Online citations, reference lists, and bibliographies.

Oral Potentially Malignant Disorders

Ketan D Patel, Deepak Kadamani, Moni A Kuriakose
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The World Health Organization (WHO) workshop in 2005 redefined all oral lesions with a potential for a malignant transformation to be grouped under the title “potentially malignant disorders.” The traditional terminologies of premalignant lesions and premalignant conditions have been abandoned. There are several lesions that fall under this title; however we will limit our discussion to the most commonly seen lesions in clinical practice; these include lichen planus, leukoplakia, erythroplakia, erythroleukoplakia, erythroplakia with ulceration, proliferative verrucous leukoplakia, and submucous fibrosis. All the aforementioned lesions are predominantly found in the oral cavity. Potentially malignant lesions of the skin can also be found in the head and neck and however are beyond the scope of this chapter and will not be discussed.
This paper references
10.1016/S0733-8635(02)00067-0
The clinical manifestations and treatment of oral lichen planus.
D. Eisen (2003)
The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut.
J. Canniff (1981)
10.1016/J.ORALONCOLOGY.2004.06.010
The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up.
P. S. van der Hem (2005)
Recent advances on the pathogenesis of oral lichen planus (OLP). The adhesion molecules.
F. Femiano (1999)
Effect on oral leukoplakia of reducing or ceasing tobacco smoking.
B. Roed-Petersen (1982)
Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.
T. Kawamori (1999)
10.1097/00005537-199906000-00021
Laser management of oral leukoplakias: a follow-up study of 70 patients.
M. Schoelch (1999)
10.1016/J.ORALONCOLOGY.2008.11.007
Defining the risk of oral premalignant lesions
Joel B. Epstein (2009)
10.1016/0964-1955(92)90035-Y
Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results.
F. Chiesa (1992)
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.
B. J. Braakhuis (2003)
10.1248/cpb.33.1725
Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L.
S. Toda (1985)
Multiple head and neck tumors: evidence for a common clonal origin.
G. Bedi (1996)
10.1093/carcin/17.6.1305
Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.
M. Pereira (1996)
10.1016/S0901-5027(87)80049-8
[Surgical treatment of premalignant lesions of the oral mucosa].
P. Holmstrup (1985)
10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
“Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin
D. Slaughter (1953)
10.5402/2012/681469
Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma
S. Krisanaprakornkit (2012)
10.1016/J.ORALONCOLOGY.2004.12.003
Oral erythroplakia--a review.
P. Reichart (2005)
10.1016/J.ORALONCOLOGY.2008.05.016
Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management
I. Waal (2009)
10.1016/0006-2952(76)90421-4
Antioxidant activity of curcumin and related compounds.
O. Sharma (1976)
10.1002/14651858.CD001829.pub4
Interventions for treating oral leukoplakia to prevent oral cancer.
Giovanni Lodi (2016)
10.1016/S1368-8375(03)00102-7
Pooled estimate of world leukoplakia prevalence: a systematic review.
S. Petti (2003)
10.1016/J.ORALONCOLOGY.2004.01.005
Betel quid without tobacco as a risk factor for oral precancers
B. Jacob (2004)
10.1089/104454702753768025
Clinical assessment of laser monotherapy for squamous cell carcinoma of the mobile tongue.
J. Ishii (2002)
Viral and molecular aspects of oral cancer.
N. S. Hillbertz (2012)
10.1016/J.ORALONCOLOGY.2005.08.011
Long-term treatment outcome of oral premalignant lesions.
P. Holmstrup (2006)
10.1111/J.1600-0714.2007.00582.X
Nomenclature and classification of potentially malignant disorders of the oral mucosa.
S. Warnakulasuriya (2007)
10.1159/000073110
Erosion and Ulceration Occurring on Oral Lichen planus. Comments on the Article ‘Erosive Lichen planus: What Is This? by A. Rebora
R. Küffer (2003)
10.1016/j.cden.2013.12.004
Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma.
Nelson L. Rhodus (2014)
10.14219/JADA.ARCHIVE.1999.0335
Oral leukoplakia status six weeks after cessation of smokeless tobacco use.
G. C. Martin (1999)
Second international cancer chemoprevention conference.
S. Benner (1994)
10.4317/medoral.18756
The relevance of uniform reporting in oral leukoplakia: Definition, certainty factor and staging based on experience with 275 patients
Elisabeth R.E.A. Brouns (2013)
10.1046/J.1365-4362.2000.00863.X
Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy.
T. Demitsu (2000)
10.1034/J.1600-0714.2003.00143.X
Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus.
E. Kawamura (2003)
10.1017/S0022215100096286
Oral submucous fibrosis--treatment with hyalase.
P. Kakar (1985)
10.1016/j.ijom.2010.03.014
Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer.
S. Y. Lee (2010)
10.1155/2010/186018
A Review of the Nonsurgical Treatment of Oral Leukoplakia
Adriana Spínola Ribeiro (2010)
10.1016/S1368-8375(00)00006-3
Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration.
A. Mashberg (2000)
10.1034/J.1601-0825.2001.70105.X
Tobacco usage in relation to the anatomical site of oral leukoplakia.
K. Schepman (2001)
10.1002/ijc.29156
Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: A randomized controlled trial
T. Nagao (2015)
10.1056/NEJM198612113152401
13-cis-retinoic acid in the treatment of oral leukoplakia.
W. Hong (1986)
10.1016/j.jpba.2012.11.017
Proteomics-based identification of plasma biomarkers in oral squamous cell carcinoma.
Chun‐Liang Tung (2013)
10.3322/canjclin.45.6.328
Early diagnosis of asymptomatic oral and oropharyngeal squamouscancers
A. Mashberg (1995)
10.1126/science.1208130
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky (2011)
10.1016/S0964-1955(96)00035-8
Prevalence study of oral white lesions with special reference to a new definition of oral leucoplakia.
K. Schepman (1996)
Oral lichen planus update: clinical characteristics, treatment responses, and malignant transformation.
S. Silverman (1997)
10.1111/J.1600-0714.2007.00513.X
Oral premalignant lesions: is a biopsy reliable?
P. Holmstrup (2007)
10.1002/1097-0142(197509)36:3<1021::AID-CNCR2820360327>3.0.CO;2-W
Erythroplakia of the oral cavity
W. Shafer (1975)
10.1016/0304-3835(95)03827-J
Anti-tumour and antioxidant activity of natural curcuminoids.
A. Ruby (1995)
10.1093/carcin/18.7.1415
Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity.
L. Tao (1997)
10.1056/NEJMRA001375
Head and neck cancer.
A. Forastiere (2001)
Diagnosis and management of oral lichen planus.
N. Rhodus (2003)
10.1016/S0002-9440(10)63649-8
Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism.
Wakana Iijima (2003)
10.1016/S1079-2104(97)90062-7
Proliferative verrucous leukoplakia
S. Silverman (1997)
10.1054/IJOM.2001.0066
Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL.
F. Femiano (2001)
10.1016/J.COMS.2006.06.003
Oral cancer prevention.
M. Kuriakose (2006)
10.1002/1097-0215(20001001)88:1<129::AID-IJC20>3.0.CO;2-U
Alcohol drinking, body mass index and the risk of oral leukoplakia in an Indian population
M. Hashibe (2000)
Retinoid chemoprevention of second primary tumors.
S. Benner (1994)
10.1016/j.cden.2014.01.001
Oral lichen planus and lichenoid mucositis.
Scott S De Rossi (2014)
10.1016/J.TRIPLEO.2005.12.009
Clinicopathologic aspects of oral leukoplakia in smokers and nonsmokers.
M. D. Freitas (2006)
10.1007/s00428-012-1290-3
Cancer of unknown primary originating from oropharyngeal carcinomas are strongly correlated to HPV positivity
P. Zengel (2012)
10.1111/j.1600-0528.1985.tb00468.x
Malignant transformation rate in oral submucous fibrosis over a 17-year period.
P. Murti (1985)
10.1016/0030-4220(91)90007-Y
A prospective study of findings and management in 214 patients with oral lichen planus.
S. Silverman (1991)
10.1016/0030-4220(85)90313-5
Proliferative verrucous leukoplakia. A long-term study of thirty patients.
L. Hansen (1985)
[Biological aspects and perspectives applicable to the chemoprevention of cancer of the upper respiratory-digestive tract].
S. Toma (1990)
10.1034/J.1600-0714.2001.300103.X
Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis.
M. Haque (2001)
10.1007/978-1-4615-4149-3_6
Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
M. Pereira (1999)
10.1111/j.1600-0714.1995.tb01165.x
Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16.
J. Palefsky (1995)
10.1007/s12663-011-0195-z
Oral Cancer: Risk Factors and Molecular Pathogenesis
Hari Ram (2011)



Semantic Scholar Logo Some data provided by SemanticScholar